132 related articles for article (PubMed ID: 29319498)
1. Safety and tolerance of cidofovir as a 2% gel for local application in high-grade cervical intraepithelial neoplasia: A phase 1 investigation.
Bossens M; Jost M; Van Pachterbeke C; De Maertelaer V; Simon P; Frankenne F; Hubert P; Evrard B; Snoeck R
Int J Clin Pharmacol Ther; 2018 Mar; 56(3):134-141. PubMed ID: 29319498
[TBL] [Abstract][Full Text] [Related]
2. Topical treatment of CIN 2+ by cidofovir: results of a phase II, double-blind, prospective, placebo-controlled study.
Van Pachterbeke C; Bucella D; Rozenberg S; Manigart Y; Gilles C; Larsimont D; Vanden Houte K; Reynders M; Snoeck R; Bossens M
Gynecol Oncol; 2009 Oct; 115(1):69-74. PubMed ID: 19647859
[TBL] [Abstract][Full Text] [Related]
3. Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT³VIN): a multicentre, open-label, randomised, phase 2 trial.
Tristram A; Hurt CN; Madden T; Powell N; Man S; Hibbitts S; Dutton P; Jones S; Nordin AJ; Naik R; Fiander A; Griffiths G
Lancet Oncol; 2014 Nov; 15(12):1361-8. PubMed ID: 25304851
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and safety of intravesicular cidofovir in allogeneic HSCT recipients.
Aitken SL; Zhou J; Ghantoji SS; Kontoyiannis DP; Jones RB; Tam VH; Chemaly RF
J Antimicrob Chemother; 2016 Mar; 71(3):727-30. PubMed ID: 26612873
[TBL] [Abstract][Full Text] [Related]
5. Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III).
Snoeck R; Noel JC; Muller C; De Clercq E; Bossens M
J Med Virol; 2000 Feb; 60(2):205-9. PubMed ID: 10596022
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of topical cidofovir to treat high-grade perianal and vulvar intraepithelial neoplasia in HIV-positive men and women.
Stier EA; Goldstone SE; Einstein MH; Jay N; Berry JM; Wilkin T; Lee JY; Darragh TM; Da Costa M; Panther L; Aboulafia D; Palefsky JM
AIDS; 2013 Feb; 27(4):545-51. PubMed ID: 23032420
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and renal effects of cidofovir with a reduced dose of probenecid in HIV-infected patients with cytomegalovirus retinitis.
Wolf DL; Rodríguez CA; Mucci M; Ingrosso A; Duncan BA; Nickens DJ
J Clin Pharmacol; 2003 Jan; 43(1):43-51. PubMed ID: 12520627
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of periungual warts with topical cidofovir.
Padilla España L; Del Boz J; Fernández Morano T; Arenas-Villafranca J; de Troya M
Dermatol Ther; 2014; 27(6):337-42. PubMed ID: 25081902
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patients.
Deutsch E; Haie-Meder C; Bayar MA; Mondini M; Laporte M; Mazeron R; Adam J; Varga A; Vassal G; Magné N; Chargari C; Lanoy E; Pautier P; Levy A; Soria JC
Oncotarget; 2016 May; 7(18):25549-57. PubMed ID: 27016411
[TBL] [Abstract][Full Text] [Related]
10. Clinical responses to Cidofovir applied topically to women with high grade vulval intraepithelial neoplasia.
Tristram A; Fiander A
Gynecol Oncol; 2005 Dec; 99(3):652-5. PubMed ID: 16169066
[TBL] [Abstract][Full Text] [Related]
11. Medical interventions for high-grade vulval intraepithelial neoplasia.
Pepas L; Kaushik S; Nordin A; Bryant A; Lawrie TA
Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD007924. PubMed ID: 26284429
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of recurrent vulvar intraepithelial neoplasia resistant to interferon and isotretinoin with cidofovir.
Koonsaeng S; Verschraegen C; Freedman R; Bossens M; Kudelka A; Kavanagh J; Sittisomwong T; DeClercq E; Snoeck R
J Med Virol; 2001 Jun; 64(2):195-8. PubMed ID: 11360253
[TBL] [Abstract][Full Text] [Related]
13. Topical cidofovir-induced acute kidney injury in two severely immunocompromised patients with refractory multidrug-resistant herpes simplex virus infections.
Saunders IM; Lahoti A; Chemaly RF; Trevino C; Westmoreland M; Hosing C
J Oncol Pharm Pract; 2016 Apr; 22(2):325-31. PubMed ID: 25488905
[TBL] [Abstract][Full Text] [Related]
14. Topical use of cidofovir induced acute renal failure.
Bienvenu B; Martinez F; Devergie A; Rybojad M; Rivet J; Bellenger P; Morel P; Gluckman E; Lebbé C
Transplantation; 2002 Feb; 73(4):661-2. PubMed ID: 11889450
[TBL] [Abstract][Full Text] [Related]
15. Urrets-Zavalia syndrome as a complication of ocular hypotonia due to intravenous cidofovir treatment.
Orssaud C; Wermert D; Roux A; Laccourreye O; Sors H; Roche O; Dufier JL
Eye (Lond); 2014 Jun; 28(6):776-7. PubMed ID: 24675584
[No Abstract] [Full Text] [Related]
16. [Treatment of cutaneous human papilloma virus, poxvirus and herpes simplex virus infections with topical cidofovir in HIV positive patients].
Toutous-Trellu L; Hirschel B; Piguet V; Schiffer V; Saurat JH; Pechère M
Ann Dermatol Venereol; 2004 May; 131(5):445-9. PubMed ID: 15235531
[TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of cidofovir in high-risk pediatric patients.
Bhadri VA; Lee-Horn L; Shaw PJ
Transpl Infect Dis; 2009 Aug; 11(4):373-9. PubMed ID: 19392729
[TBL] [Abstract][Full Text] [Related]
18. Topical cidofovir to treat high-grade anal intraepithelial neoplasia in HIV-infected patients: a pilot clinical trial.
Sendagorta E; Bernardino JI; Álvarez-Gallego M; Feíto M; Feltes R; Beato MJ; Pérez-Molina JA; Yllescas M; Díaz-Almirón M; Arribas JR; González-García J; Herranz P;
AIDS; 2016 Jan; 30(1):75-82. PubMed ID: 26731755
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic paint of cidofovir/sucralfate gel combination topically administered by spraying for treatment of orf virus infections.
Sonvico F; Colombo G; Gallina L; Bortolotti F; Rossi A; McInnes CJ; Massimo G; Colombo P; Scagliarini A
AAPS J; 2009 Jun; 11(2):242-9. PubMed ID: 19381838
[TBL] [Abstract][Full Text] [Related]
20. Treatment of recurrent respiratory papillomatosis and adverse reactions following off-label use of cidofovir (Vistide®).
Tjon Pian Gi RE; Dietz A; Djukic V; Eckel HE; Friedrich G; Golusinski W; Hantzakos A; Lawson G; Remacle M; Rihkanen H; Dikkers FG
Eur Arch Otorhinolaryngol; 2012 Feb; 269(2):361-2. PubMed ID: 22020697
[No Abstract] [Full Text] [Related]
[Next] [New Search]
